NEW YORK (GenomeWeb) – Danaher today reported that total sales for the second quarter rose 10 percent year over year and beat the consensus Wall Street estimate. 

For the three months ending June 29, the Washington, DC-based conglomerate posted $4.98 billion in sales, up from $4.51 billion in Q2 2017. Analysts' average sales estimate was $4.92 billion. 

Organically, sales were up 6 percent year over year. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.